YARS1

Across TCGA pan-cancer cohorts, YARS1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated YARS1 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher YARS1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated YARS1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where YARS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.891	1.000	.004	25	view →
PDAC	OS	Quartile	All	0.268	0.596	.003	22	view →
LUAD	OS	Median	All	0.549	0.882	.001	16	view →
HNSC	DFS	Tertile	IV	0.888	0.637	.012	10	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
GBM	DFS	Median	All	0.212	0.315	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

YARS1–CCRCC (OS)

Open the CCRCC breakdown →